WO2003078960A3 - Analysis of sulfated polysaccharides - Google Patents

Analysis of sulfated polysaccharides Download PDF

Info

Publication number
WO2003078960A3
WO2003078960A3 PCT/US2003/007208 US0307208W WO03078960A3 WO 2003078960 A3 WO2003078960 A3 WO 2003078960A3 US 0307208 W US0307208 W US 0307208W WO 03078960 A3 WO03078960 A3 WO 03078960A3
Authority
WO
WIPO (PCT)
Prior art keywords
sulfated polysaccharides
products
analysis
analyzing
methods
Prior art date
Application number
PCT/US2003/007208
Other languages
French (fr)
Other versions
WO2003078960A2 (en
Inventor
Ganesh Venkataraman
Ram Sasisekharan
Malikarjun Sundaram
Zachary Shriver
Yi-Wei Qi
Original Assignee
Momenta Pharmaceuticals Inc
Ganesh Venkataraman
Ram Sasisekharan
Malikarjun Sundaram
Zachary Shriver
Yi-Wei Qi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28046489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003078960(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Momenta Pharmaceuticals Inc, Ganesh Venkataraman, Ram Sasisekharan, Malikarjun Sundaram, Zachary Shriver, Yi-Wei Qi filed Critical Momenta Pharmaceuticals Inc
Priority to CA2478700A priority Critical patent/CA2478700C/en
Priority to AU2003225724A priority patent/AU2003225724A1/en
Priority to JP2003576923A priority patent/JP4828795B2/en
Priority to EP03744629A priority patent/EP1518120A4/en
Publication of WO2003078960A2 publication Critical patent/WO2003078960A2/en
Publication of WO2003078960A3 publication Critical patent/WO2003078960A3/en
Priority to AU2009200769A priority patent/AU2009200769B2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/17—Nitrogen containing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Abstract

The invention relates to methods and products associated with analyzing and monitoring heterogeneous populations of sulfated polysaccharides. In particular therapeutic heparin products including low molecular weight heparin products and methods of analyzing and monitoring these products are described.
PCT/US2003/007208 2002-03-11 2003-03-11 Analysis of sulfated polysaccharides WO2003078960A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2478700A CA2478700C (en) 2002-03-11 2003-03-11 Analysis of sulfated polysaccharides
AU2003225724A AU2003225724A1 (en) 2002-03-11 2003-03-11 Analysis of sulfated polysaccharides
JP2003576923A JP4828795B2 (en) 2002-03-11 2003-03-11 Analysis of sulfated polysaccharides
EP03744629A EP1518120A4 (en) 2002-03-11 2003-03-11 Analysis of sulfated polysaccharides
AU2009200769A AU2009200769B2 (en) 2002-03-11 2009-02-26 Analysis of sulfated polysaccharides

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US36324002P 2002-03-11 2002-03-11
US60/363,240 2002-03-11
US38390302P 2002-05-28 2002-05-28
US60/383,903 2002-05-28
US39397302P 2002-07-05 2002-07-05
US60/393,973 2002-07-05

Publications (2)

Publication Number Publication Date
WO2003078960A2 WO2003078960A2 (en) 2003-09-25
WO2003078960A3 true WO2003078960A3 (en) 2005-01-27

Family

ID=28046489

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/007208 WO2003078960A2 (en) 2002-03-11 2003-03-11 Analysis of sulfated polysaccharides

Country Status (6)

Country Link
US (5) US7575886B2 (en)
EP (3) EP1518120A4 (en)
JP (2) JP4828795B2 (en)
AU (2) AU2003225724A1 (en)
CA (1) CA2478700C (en)
WO (1) WO2003078960A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000065521A2 (en) 1999-04-23 2000-11-02 Massachusetts Institute Of Technology System and method for polymer notation
BE1015608A6 (en) * 2003-07-15 2005-06-07 Messadek Jallal TREATMENT arteritis.
WO2003078960A2 (en) 2002-03-11 2003-09-25 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
US7508206B2 (en) * 2002-05-20 2009-03-24 Massachusetts Institute Of Technology Method for sequence determination using NMR
US6962699B2 (en) * 2002-06-03 2005-11-08 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase B
US20040171819A1 (en) 2002-10-10 2004-09-02 Aventis Pharma S.A. Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
DE602004003577T2 (en) * 2003-04-17 2007-09-20 Jallal Messadek Floating oral formulations with controlled release of betaine
US20060128657A1 (en) * 2003-08-04 2006-06-15 Jallal Messadek Selected betaines and their uses
WO2005026720A1 (en) * 2003-09-04 2005-03-24 Parivid Llc Methods and apparatus for characterizing polymeric mixtures
EP1537871A1 (en) * 2003-12-04 2005-06-08 Aventis Pharma S.A. Enoxaparin for the treatment of cancer
BE1016128A6 (en) * 2004-07-22 2006-03-07 Messadek Jallal Combination therapy
WO2006050581A2 (en) * 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
FR2880951B1 (en) * 2005-01-19 2015-09-18 Aventis Pharma Sa METHOD OF ANALYZING OLIGOSACCHARIDES FROM BLOOD PLASMA
MX2007013486A (en) * 2005-04-27 2008-03-14 Jallal Messadek Insulins combinations.
DE102005038418A1 (en) * 2005-08-12 2007-02-15 Dade Behring Marburg Gmbh Factor Xa-based heparin assay using a heparin-modifying component
EP2404939A3 (en) 2006-05-25 2012-03-21 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
US8101733B1 (en) * 2006-06-27 2012-01-24 Momenta Pharmaceuticals, Inc. Methods of evaluating mixtures of polysaccharides
US20080051702A1 (en) * 2006-08-24 2008-02-28 Herrmann Robert A Therapeutic agent delivery for the treatment of asthma via implantable and insertable medical devices
US7968082B1 (en) 2007-01-26 2011-06-28 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by NMR
US7790466B1 (en) 2007-01-26 2010-09-07 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by chain profiles or chain mapping
WO2008124021A1 (en) * 2007-04-03 2008-10-16 Clavina Diagnostics, Inc. Method of detecting red cell antigen-antibody reactions
PT2135091E (en) * 2007-04-16 2011-09-01 Momenta Pharmaceuticals Inc Ms methods to evaluate glycans
ES2444705T3 (en) * 2007-07-24 2014-02-26 Active Biomaterials Llc Method for measuring the concentration of a glycosaminoglycan anticoagulant
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
EP2205642B1 (en) 2007-11-02 2016-01-27 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
US20110076729A1 (en) * 2008-02-20 2011-03-31 Momenta Pharmaceuticals, Inc. Methods of making low molecular weight heparin compositions
JP5685381B2 (en) * 2009-03-13 2015-03-18 Ｊｃｒファーマ株式会社 Analysis method of saccharides
WO2011038047A1 (en) * 2009-09-23 2011-03-31 Momenta Pharmaceuticals, Inc. Methods of treatment with a low molecular weight heparin composition
CN102791742B (en) 2010-01-19 2014-12-24 动量制药公司 Evaluating heparin preparations
JP5982361B2 (en) 2010-04-16 2016-08-31 モメンタ ファーマシューティカルズ インコーポレイテッド Tissue targeting method
US10017585B2 (en) 2010-06-17 2018-07-10 Momenta Pharmaceuticals, Inc. Methods and compositions for promoting hair growth
KR101847846B1 (en) * 2010-09-14 2018-04-11 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 High purity heparin and production method therefor
CN102792158B (en) * 2011-01-28 2013-07-10 杭州九源基因工程有限公司 Fine structure determination method of enoxaparin sodium based on capillary electrophoresis
WO2012115952A1 (en) * 2011-02-21 2012-08-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
CN102759596B (en) * 2012-07-09 2014-08-20 山东大学 Method for detecting low-molecular-weight heparin by combining ion pair reversed phase chronmatogaphy and mass spectrum
EP3003324A4 (en) 2013-05-28 2017-01-25 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions
EP3003323A4 (en) * 2013-05-28 2016-12-28 Momenta Pharmaceuticals Inc Polysaccharide compositions and related methods
CN104280490B (en) * 2013-07-02 2016-03-02 南通中国科学院海洋研究所海洋科学与技术研究发展中心 A kind of mass analysis method of algal polysaccharide sulfate
WO2015065986A1 (en) * 2013-10-29 2015-05-07 Bloodcenter Research Foundation Method of detecting platelet activating antibodies that cause heparin-induced thrombocytopenia/thrombosis
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
EA202190416A1 (en) 2018-08-02 2021-06-23 Дайн Терапьютикс, Инк. MUSCULAR-SPECIFIC COMPLEXES AND THEIR APPLICATION FOR THE TREATMENT OF SHOULDER-SCAPULAR-FACIAL MUSCULAR DYSTROPHY
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CN108828103B (en) * 2018-08-21 2021-02-19 辽宁省农业科学院 Morchella HPCE fingerprint establishing method and standard fingerprint thereof
CN109596742B (en) * 2018-12-25 2022-04-26 深圳市格利科生物科技有限公司 Method for detecting content of main components in heparan sulfate finished product
CN111304229A (en) * 2019-12-11 2020-06-19 泉州师范学院 Heparinase gene engineering expression product and preparation method thereof
CA3169898A1 (en) * 2020-03-23 2021-09-30 Atossa Therapeutics, Inc. Heparin and n-acetylcysteine for the treatment of a respiratory virus
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11931421B2 (en) 2022-04-15 2024-03-19 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990003791A1 (en) * 1988-10-05 1990-04-19 Nicola Diferrante Methods for interfering with hiv multiplication and composition for the treatment of aids

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
SE447872B (en) 1977-08-08 1986-12-22 Choay Sa METAL SALT OF HEPARIN OF INJECTABLE QUALITY AND PROCEDURE FOR ITS PREPARATION
US4692435A (en) 1978-11-06 1987-09-08 Choay, S.A. Mucopolysaccharide composition having a regulatory action on coagulation, medicament containing same and process of preparation
FR2478646A2 (en) 1980-03-20 1981-09-25 Choay Sa MUCOPOLYSACCHARIDIC COMPOSITION HAVING A COAGULATION REGULATING ACTIVITY, MEDICAMENT CONTAINING THE SAME, AND METHOD FOR OBTAINING THE SAME
US4826827A (en) 1979-10-05 1989-05-02 Choay S.A. Short chained oligosaccharides having biological properties, a process for making the same and the use thereof as drugs
FR2503714B1 (en) 1981-04-10 1986-11-21 Choay Sa PROCESS FOR OBTAINING BIOLOGICALLY ACTIVE MUCOPOLYSACCHARIDES, OF HIGH PURITY, BY DEPOLYMERIZATION OF HEPARIN
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
IT1195497B (en) 1983-03-08 1988-10-19 Opocrin Spa PROCEDURE FOR THE PREPARATION OF OLIGOSACCHARIDIC FRACTIONS EQUIPPED WITH PHARMACOLOGICAL PROPERTIES FOR CHEMICAL DEGRADATION OF HEPARIN
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US4687765A (en) 1983-07-25 1987-08-18 Choay S.A. Method and composition for thrombolytic treatment
US4847338A (en) 1985-03-28 1989-07-11 University Of Iowa Research Foundation Low molecular weight heparin fragments as inhibitors of complement activation
US4916219A (en) 1985-03-28 1990-04-10 University Of Iowa Research Foundation Oligosaccharide heparin fragments as inhibitors of complement cascade
FR2584728B1 (en) 1985-07-12 1987-11-20 Choay Sa PROCESS FOR THE SULFATION OF GLYCOSAMINOGLYCANS AND THEIR FRAGMENTS
US5106734A (en) 1986-04-30 1992-04-21 Novo Nordisk A/S Process of using light absorption to control enzymatic depolymerization of heparin to produce low molecular weight heparin
DK196986D0 (en) 1986-04-30 1986-04-30 Novo Industri As PREPARATION OF POLYSACCHARIDES
DK196886D0 (en) 1986-04-30 1986-04-30 Novo Industri As PREPARATION OF POLYSACCHARIDES
DE3787996T2 (en) 1986-05-16 1994-03-03 Italfarmaco Spa Heparin free from E.D.T.A., fractions and fragments of heparin, processes for their preparation and pharmaceutical compositions containing them.
AR243204A1 (en) 1986-11-21 1993-07-30 Ajorca Sa A method for the chemical depolymerisation of polysaccharides.
ES2003197A6 (en) 1987-01-05 1988-10-16 Rovi Lab Farmaceut Sa Process for the depolymerization of heparin for obtaining heparin with a low molecular weight and having an antithrombotic activity.
FR2614026B1 (en) 1987-04-16 1992-04-17 Sanofi Sa LOW MOLECULAR WEIGHT HEPARINS WITH REGULAR STRUCTURE, THEIR PREPARATION AND THEIR BIOLOGICAL APPLICATIONS
SE8702254D0 (en) 1987-05-29 1987-05-29 Kabivitrum Ab NOVEL HEPARIN DERIVATIVES
US4933472A (en) 1988-04-08 1990-06-12 Yamanouchi Pharmaceutical Co., Ltd. Substituted aminomethylenebis(phosphonic acid) derivatives
EP0337327A1 (en) 1988-04-09 1989-10-18 Bioiberica, S.A. Process for the preparation of new oligosaccharide fractions by controlled chemical depolimerization of heparin
US5264425A (en) 1988-06-03 1993-11-23 Italfarmaco S.P.A. Glycosaminoglycan salts and pharmaceutical compositions containing them
IT1234508B (en) 1988-06-10 1992-05-19 Alfa Wassermann Spa HEPARIN DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION
US4981955A (en) 1988-06-28 1991-01-01 Lopez Lorenzo L Depolymerization method of heparin
US5380716A (en) 1988-12-15 1995-01-10 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
US5032679A (en) 1988-12-15 1991-07-16 Glycomed, Inc. Heparin fragments as inhibitors of smooth muscle cell proliferation
IT1234826B (en) 1989-01-30 1992-05-29 Alfa Wassermann Spa HEPARIN DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION
US5340932A (en) 1989-08-18 1994-08-23 Ajorca S.A. Substances with heparin-like structure and their method of production
IT1237518B (en) 1989-11-24 1993-06-08 Renato Conti SUPER-SULFATED HEPARINS
FR2663639B1 (en) 1990-06-26 1994-03-18 Rhone Poulenc Sante LOW MOLECULAR WEIGHT POLYSACCHARIDE BLENDS PROCESS FOR PREPARATION AND USE.
USRE38743E1 (en) 1990-06-26 2005-06-14 Aventis Pharma S.A. Mixtures of particular LMW heparinic polysaccharides for the prophylaxis/treatment of acute thrombotic events
IT1243987B (en) 1990-10-29 1994-06-28 Derivati Organici Lab PROCEDURE FOR THE PREPARATION OF EPOXY-HEPARID PRODUCTS OBTAINED PHARMACEUTICAL ECOMPOSITIONS CONTAINING THEM
JPH04167172A (en) 1990-10-31 1992-06-15 Nec Corp Vector processor
US5707973A (en) 1991-04-23 1998-01-13 Rhone-Poulenc Rorer S.A. Sulfated polysaccharids for treatment or prevention of thromboses
FR2682388B1 (en) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc PROCESS FOR THE PREPARATION OF AN OLIGOSIDE BY DEPOLYMERIZATION OF A POLYOSIDE DERIVED FROM A PATHOGENIC AGENT, OLIGOSIDE THUS OBTAINED AND ITS USE IN PARTICULAR AS A VACCINE AGENT.
FR2687158B1 (en) 1992-02-07 1995-06-30 Rhone Poulenc Rorer Sa SULPHATE POLYSACCHARIDES, METHOD OF PREPARATION, PHARMACEUTICAL COMPOSITION AND USE.
US5849721A (en) 1992-02-07 1998-12-15 Rhone-Poulenc Rorer S.A. Sulfated polysaccharides obtained from heparin, preparation process, pharmaceutical composition and use thereof
IT1254216B (en) 1992-02-25 1995-09-14 Opocrin Spa POLYSACCHARIDIC DERIVATIVES OF HEPARIN, EPARAN SULPHATE, THEIR FRACTIONS AND FRAGMENTS, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
IT1260136B (en) 1992-04-17 1996-03-28 Alfa Wassermann Spa SEMI-SYNTHETIC GLYCOSAMINOGLICANS CONTAINING ALPHA-L-GALACTURONIC ACID REPLACED WITH NUCLEOPHILIC RADICALS IN POSITION 3
IT1260137B (en) 1992-04-17 1996-03-28 Alfa Wassermann Spa SEMI-SYNTHETIC GLYCOSAMINOGLICANS WITH EPARINIC OR EPARANIC STRUCTURE MODIFIED IN POSITION 2 OF ALPHA-L-IDURONIC-2-0-SULPHATE ACID
US6750207B1 (en) 1992-05-01 2004-06-15 Yeda Research And Development Co. Ltd. Compositions for the regulation of cytokine activity
US5668118A (en) 1992-07-24 1997-09-16 Cavalier Pharmaceuticals Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G
US5292416A (en) * 1992-11-13 1994-03-08 Indiana University Foundation Pulsed-field separation of polysaccharides in capillaries
US5296471A (en) 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
US5696100A (en) 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
IT1264102B1 (en) 1993-03-29 1996-09-10 Alfa Wassermann Spa PROCESS FOR THE SYNTHESIS OF SEMI-SYNTHETIC GLYCOSAMINOGLICANS CONTAINING ALPHA-L-GALACTURONIC ACID SUBSTITUTED WITH RADICALS
FR2704861B1 (en) 1993-05-07 1995-07-28 Sanofi Elf Purified heparin fractions, process for obtaining them and pharmaceutical compositions containing them.
IT1264709B1 (en) 1993-07-12 1996-10-04 Italfarmaco Spa HEPARINIC DERIVATIVES WITH ANTI-METASTASTIC ACTIVITY
JPH0797256A (en) * 1993-09-24 1995-04-11 Ngk Spark Plug Co Ltd Sintered body of aluminum oxide base and its production
US6255296B1 (en) 1994-01-11 2001-07-03 Endomatrix, Inc. Composition and method for treating a patient susceptible to or suffering from a cardiovascular disorder or disease
US5607859A (en) 1994-03-28 1997-03-04 Massachusetts Institute Of Technology Methods and products for mass spectrometric molecular weight determination of polyionic analytes employing polyionic reagents
US6228998B1 (en) 1994-07-22 2001-05-08 Seikagaku Kogyo Kabushiki Kaisha Amino spacered glycosaminoglycan derivatives and their use in copolymerization with acrylamide
FR2723847A1 (en) 1994-08-29 1996-03-01 Debiopharm Sa HEPARIN - BASED ANTITHROMBOTIC AND NON - HEMORRHAGIC COMPOSITIONS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC APPLICATIONS.
IT1271057B (en) 1994-11-04 1997-05-26 Inalco Spa POLYSACCHARIDES HAVING A HIGH CONTENT OF HYDURONIC ACID
DE69623840D1 (en) 1995-03-31 2002-10-31 Hamilton Civic Hospitals Res Composition for inhibiting the development of thrombosis
AUPN261895A0 (en) 1995-04-28 1995-05-18 Australian National University, The Preparation and use of sulfated oligosaccharides
US6217863B1 (en) 1995-10-30 2001-04-17 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase I
JPH09133960A (en) 1995-11-07 1997-05-20 Fuji Photo Optical Co Ltd Bifocal switchable camera
US5843786A (en) 1995-11-28 1998-12-01 Neose Technologies, Inc. Analysis of carbohydrates in biological fluids by high performance liquid chromatography
EP0781566B1 (en) 1995-12-26 2004-07-28 Toyo Boseki Kabushiki Kaisha Organic solvent-soluble mucopolysaccharide, antibacterial antithrombogenic composition and medical material
US5935850A (en) 1996-09-30 1999-08-10 The Research Foundation Of State University Of New York Model for cell migration and use thereof
US5767269A (en) 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
IT1290814B1 (en) 1997-03-24 1998-12-11 Istituto Scient Di Chimica E B GLYCOSAMINOGLICANS WITH HIGH ANTI-THROMBOTIC ACTIVITY
WO1998055515A1 (en) 1997-06-06 1998-12-10 Hamilton Civic Hospitals Research Development, Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
HU225240B1 (en) 1997-07-16 2006-08-28 Akzo Nobel Nv Process for the production of heparin
US5965535A (en) 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
JPH11230935A (en) 1998-02-18 1999-08-27 Yokogawa Analytical Systems Inc Method and device for analyzing saccharide by capillary electrophoresis
US6475361B1 (en) * 1998-02-20 2002-11-05 Tetragen Sa Capillary electrophoresis apparatus having filling/refilling system and methods for use thereof
US6492503B1 (en) 1998-07-31 2002-12-10 Seikagaku Corporation Glycosaminoglycan and drug compositions containing the same
EA200100965A1 (en) 1999-03-11 2002-08-29 Дюпон Фармасьютикалз Компани SYNERGISM BETWEEN LOW MOLECULAR HEPARIN AND INHIBITORS AGAINSTATION OF PLATELETS THAT PROVIDES COMBINED THERAPY FOR PREVENTION AND TREATMENT OF DIFFERENT THROMBOEMBOLIC DISORDERS
WO2000065521A2 (en) 1999-04-23 2000-11-02 Massachusetts Institute Of Technology System and method for polymer notation
US7335716B1 (en) 1999-06-17 2008-02-26 Mitsui Chemicals, Inc. Ethylene (co)polymers and uses thereof
JP3990910B2 (en) * 1999-07-16 2007-10-17 アプレラ コーポレイション High density electrophoresis device and method
ES2161615B1 (en) 1999-07-23 2003-03-16 Rovi Lab Farmaceut Sa COMPOSITIONS OF HEPARINS OF VERY LOW MOLECULAR WEIGHT.
US6258798B1 (en) 1999-09-07 2001-07-10 Pharmacia Ab Method for treatment of unstable coronary artery disease by an early revascularisation together with administration of a low molecular weight heparin
US6617316B1 (en) 1999-10-22 2003-09-09 Aventis Pharma Oligosaccharides, their preparation and pharmaceutical compositions containing them
FR2800074B1 (en) 1999-10-22 2001-12-21 Aventis Pharma Sa NOVEL OLIGOSACCHARIDES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ATE279929T1 (en) 2000-01-10 2004-11-15 Dieter Welzel USE OF A MEDIUM MOLEWORK HEPARIN
JP2003525946A (en) 2000-03-08 2003-09-02 マサチューセッツ インスティテュート オブ テクノロジー Heparinase III and uses thereof
JP3597754B2 (en) * 2000-04-24 2004-12-08 Ｎｅｃエレクトロニクス株式会社 Semiconductor device and manufacturing method thereof
EP1319183B1 (en) 2000-09-12 2009-03-25 Massachusetts Institute Of Technology Methods and products related to low molecular weight heparin
AU2440802A (en) 2000-10-18 2002-04-29 Massachusetts Inst Technology Methods and products related to pulmonary delivery of polysaccharides
US6812221B2 (en) 2000-11-21 2004-11-02 The Texas A&M University System FGF-affinity chromatography
WO2003078960A2 (en) 2002-03-11 2003-09-25 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
FR2844808B1 (en) 2002-09-23 2005-02-25 Aventis Pharma Sa METHOD OF DETERMINING SPECIFIC GROUPS CONSISTING OF HEPARINS OR HEPARINS OF LOW MOLECULAR WEIGHT
KR20050057550A (en) 2002-09-23 2005-06-16 아방티 파르마 소시에테 아노님 Method of determining specific groups forming heparins
US20040265943A1 (en) 2002-09-23 2004-12-30 Aventis Pharma S.A. Method for quantitatively determining specific groups constituting heparins or low molecular weight heparins
FR2857811A1 (en) 2003-07-16 2005-01-21 St Microelectronics Sa Compressed audio/video data flow encrypting method for wireless transmission system, involves encrypting part of packet bits of audio or video data that are defined by two consecutive timing marks, by random pseudo flow
WO2005026720A1 (en) 2003-09-04 2005-03-24 Parivid Llc Methods and apparatus for characterizing polymeric mixtures
EP1586588A1 (en) 2004-03-24 2005-10-19 Aventis Pharma S.A. Method for determining specific groups constituting heparins or low molecular weight heparins using reversed phase column chromatography
US20050186679A1 (en) 2004-02-24 2005-08-25 Christian Viskov Method for determining specific groups constituting heparins or low molecular weight heparins
EP1582531A1 (en) 2004-03-24 2005-10-05 Aventis Pharma S.A. Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products
EP1580197A1 (en) 2004-03-24 2005-09-28 Aventis Pharma S.A. Method for quantitatively determining specific groups constituting heparins or low molecular wieght heparins using HPLC
CA2565913A1 (en) 2004-05-07 2005-11-17 The University Of Queensland Composition for stimulating bone growth and differentiation and method for isolating same
FR2880951B1 (en) 2005-01-19 2015-09-18 Aventis Pharma Sa METHOD OF ANALYZING OLIGOSACCHARIDES FROM BLOOD PLASMA
US7691612B2 (en) 2005-11-03 2010-04-06 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
US7767420B2 (en) 2005-11-03 2010-08-03 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
EP2404939A3 (en) 2006-05-25 2012-03-21 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
US8101733B1 (en) 2006-06-27 2012-01-24 Momenta Pharmaceuticals, Inc. Methods of evaluating mixtures of polysaccharides
US7790466B1 (en) 2007-01-26 2010-09-07 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by chain profiles or chain mapping
US7968082B1 (en) 2007-01-26 2011-06-28 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by NMR
US8216851B2 (en) 2007-04-16 2012-07-10 Momenta Pharmaceuticals, Inc. Characterization of N-glycan mixtures by nuclear magnetic resonance
ES2444705T3 (en) 2007-07-24 2014-02-26 Active Biomaterials Llc Method for measuring the concentration of a glycosaminoglycan anticoagulant
CN102791742B (en) 2010-01-19 2014-12-24 动量制药公司 Evaluating heparin preparations
US9818601B1 (en) 2016-09-28 2017-11-14 Asm Ip Holding B.V. Substrate processing apparatus and method of processing substrate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990003791A1 (en) * 1988-10-05 1990-04-19 Nicola Diferrante Methods for interfering with hiv multiplication and composition for the treatment of aids

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ALBAN S. AND GASTPAR R.: "Development Of Spc-Elisa: A New Assay Principle For The Study Of Sulfated Polysaccharide-Protein Interactions", JOURNAL OF BIOMOLECULAR SCREENING, vol. 6, no. 6, 2001, pages 393 - 400, XP009006013 *
ARAKI Y. ET AL: "Application of 2-aminopyridine fluorescence labeling in the analysis of in vivo and in vitro metabolism of dextran sulfate sodium by size-exclusion high-performance liquid chromatography", JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL SCIENCES AND APPLICATIONS, vol. 753, no. 2, 2001, pages 209 - 215, XP004230280 *
DAWES J. ET AL: "The Measurement Of Heparin And Other Therapeutic Sulphated Polysaccharides In Plasma, Serum And Urine", TROMBOSIS AND HAEMOSTASIS, vol. 54, no. 3, 1985, pages 630 - 634, XP000121075 *
GUIZZARDI S. ET AL: "Pharmacokinetics and organ distribution in rats of a low molecular weight heparin", ARZNEIMITTEL-FORSCHUNG, vol. 37, no. 11, November 1987 (1987-11-01), pages 1281 - 1283, XP002903645 *
JESKE W. ET AL: "Pharmacologic profile of certoparin", EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 8, no. 3, 1999, pages 315 - 327, XP002903617 *
KUHLE S. ET AL: "A pharmacokinetic study of tinzaparin in pediatric patients", BLOOD, vol. 100, no. 11, 16 November 2002 (2002-11-16), XP002903646 *
VAN PUTTEN J. ET AL: "Determination of low molecular weight heparin in clinical laboratory", HAEMOSTASIS, vol. 14, no. 2, 1984, pages 205 - 210, XP002903651 *
WATT D.K. ET AL: "Comparison of ovine, bovine and porcine mucosal heparins and low molecular weight heparins by disaccharide analyses and <13>C NMR", CARBOHYDRATE POLYMERS, vol. 33, 1997, pages 5 - 11, XP004083146 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin

Also Published As

Publication number Publication date
AU2003225724A1 (en) 2003-09-29
AU2009200769B2 (en) 2011-08-25
US20030203385A1 (en) 2003-10-30
JP4828795B2 (en) 2011-11-30
AU2009200769A1 (en) 2009-03-19
EP2402753A1 (en) 2012-01-04
US20090061411A1 (en) 2009-03-05
US20110288046A1 (en) 2011-11-24
EP1518120A4 (en) 2008-08-13
US7947507B2 (en) 2011-05-24
EP2284535A1 (en) 2011-02-16
JP2006507473A (en) 2006-03-02
EP1518120A2 (en) 2005-03-30
US20140057358A1 (en) 2014-02-27
US20130065852A1 (en) 2013-03-14
US8715953B2 (en) 2014-05-06
US7575886B2 (en) 2009-08-18
CA2478700A1 (en) 2003-09-25
JP2009175143A (en) 2009-08-06
WO2003078960A2 (en) 2003-09-25
CA2478700C (en) 2012-10-16

Similar Documents

Publication Publication Date Title
WO2003078960A3 (en) Analysis of sulfated polysaccharides
ATE426805T1 (en) METHODS AND PRODUCTS ASSOCIATED WITH LOW MOLECULAR HEPARIN
AU2003245252A8 (en) Enhanced sulfated polysaccharide formulations, methods and preparations and their uses thereof
EP1550674A4 (en) Chitosan-containing polysaccharide, process for producing the same and use thereof
AU2003299817A8 (en) Genetic polymorphisms associated with stenosis, methods of detection and uses thereof
AU2003225516A1 (en) Responsive biomedical composites
BR0309755A (en) Aroma Particles
EP1853158B8 (en) Balanced physiological monitoring and treatment system
WO2002045708A3 (en) Use of zwitterionic polysaccharides for the specific modulation of immune processes
WO2003090696A3 (en) Methods and products for mucosal delivery
AU2002309750A1 (en) Screening, diagnostic and therapeutic methods relating to riz
MXPA03008771A (en) Dough, products and methods.
NO20050245L (en) Process for the preparation of N-acyl (epi) K5-amine-o-sulfate derivatives and the products thus obtained
FI20021149A0 (en) The probe system, the probe system receiver and the signal processing method in the probe receiver
AU2003245625A1 (en) Strand-reinforced elastomeric composite laminates, garments including the laminates, and methods of making the laminates
WO2004032850A3 (en) Uses of human zven antagonists
AUPS180802A0 (en) Preserved sugar cane process and equipment
DE60312494D1 (en) OPTICALLY ACTIVE PYRIDINE DERIVATIVE AND MEDICAMENT THAT CONTAINS THIS
AU2003243198A1 (en) Moisture transpiration composite and products therefrom
BR0310126B1 (en) Preservation method of wood product, and wood product having insecticidal / acaricidal properties.
AU2003258776A8 (en) Methods for obtaining oligomannuronates et guluronates, products obtained and use thereof
WO2003100088A3 (en) Method and kit for measuring mitochondrial activity in human lymphocytes
ITMI20021295A0 (en) PROCEDURE FOR THE PRODUCTION OF PRODUCTS WITH FIBERS IN GENERAL AND PANELS IN PARTICULAR, SYSTEM FOR ITS IMPLEMENTATION AS WELL AS PRODUCTS
WO2003014391A3 (en) Method for the detection of a polymorphism in cpb2
AU2003241037A1 (en) Methods for the detection of polymorphisms in human gpr50

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003744629

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003225724

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2478700

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003576923

Country of ref document: JP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003744629

Country of ref document: EP